Dr. Peter C. Enzinger, DR
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Warren Alpert Medical School of Brown University (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 135
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: Warren Alpert Medical School of Brown University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MA license 160952
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- Beth Israel Deaconess Medical Center Boston, MA
- Brigham and Women Faulkner Hospital Jamaica Plain, MA
Medical groups
- Dana-Farber Cancer Institute, Inc. (684 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 135
- Services billed
- 442
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 172 | 80 |
| Established patient office or other outpatient visit, 30-39 minutes | 86 | 45 |
| New patient office or other outpatient visit, 60-74 minutes | 45 | 45 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Dexamethasone Other prescribers in Boston, MA | 23 |
| Prochlorperazine Maleate Other prescribers in Boston, MA | 19 |
| Ondansetron Hcl Other prescribers in Boston, MA | 16 |
| Loperamide (loperamide hcl) Other prescribers in Boston, MA | 14 |
| Oxycodone Hcl Other prescribers in Boston, MA | 14 |
| Sodium Chloride (0.9 % sodium chloride) Other prescribers in Boston, MA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 14 payments worth $40,696 in total to this clinician.
| Merck Sharp & Dohme LLC | $19,520 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $6,010 |
| Amgen Inc. | $3,430 |
| Jazz Pharmaceuticals Inc. | $3,098 |
| Bayer HealthCare Pharmaceuticals Inc. | $2,800 |
| Astellas Pharma Global Development | $2,704 |
| Gilead Sciences, Inc. | $2,540 |
| Lantheus Medical Imaging, Inc. | $595 |
| Consulting Fee | $37,329 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $3,098 |
| Food and Beverage | $270 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Jan 15, 2025 | Consulting Fee KEYTRUDA · ONCOLOGY Company’s descriptionProvided as part of a research engagement. | $19,520 |
| Jazz Pharmaceuticals Inc. Feb 24, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $3,098 |
| Amgen Inc. Nov 25, 2025 | Consulting Fee | $2,744 |
| Astellas Pharma Global Development Jan 24, 2025 | Consulting Fee Vyloy · Oncology | $2,704 |
| Gilead Sciences, Inc. Jul 2, 2025 | Consulting FeeCompany’s description;4146665;VEM US;10235023 | $2,540 |
| AstraZeneca Pharmaceuticals LP Jun 12, 2025 | Consulting Fee IMFINZI · Oncology | $2,460 |
| AstraZeneca Pharmaceuticals LP Feb 25, 2025 | Consulting Fee | $2,460 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 11, 2025 | Consulting Fee | $2,100 |
| AstraZeneca Pharmaceuticals LP Nov 4, 2025 | Consulting Fee IMFINZI · Oncology | $820 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 18, 2025 | Consulting Fee | $700 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Nov 25, 2025 | Consulting Fee | $2,744 |
| Lantheus Medical Imaging, Inc. Nov 17, 2025 | Consulting Fee | $595 |
| AstraZeneca Pharmaceuticals LP Nov 4, 2025 | Consulting Fee IMFINZI · Oncology | $820 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 18, 2025 | Consulting Fee | $700 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 11, 2025 | Consulting Fee | $2,100 |
| Gilead Sciences, Inc. Jul 2, 2025 | Consulting FeeCompany’s description;4146665;VEM US;10235023 | $2,540 |
| AstraZeneca Pharmaceuticals LP Jun 12, 2025 | Consulting Fee IMFINZI · Oncology | $2,460 |
| Amgen Inc. Jun 3, 2025 | Consulting Fee | $686 |
| AstraZeneca Pharmaceuticals LP Feb 25, 2025 | Consulting Fee | $2,460 |
| Jazz Pharmaceuticals Inc. Feb 24, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $3,098 |
| Astellas Pharma Global Development Jan 24, 2025 | Consulting Fee Vyloy · Oncology | $2,704 |
| Merck Sharp & Dohme LLC Jan 15, 2025 | Consulting Fee KEYTRUDA · ONCOLOGY Company’s descriptionProvided as part of a research engagement. | $19,520 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $215,891 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib E7080,MK-7902 plus Pembrolizumab MK-3475 plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participant…
Merck Sharp & Dohme LLC - A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced …
Merck Sharp & Dohme LLC - A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab MK-3475 Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy KEYNOTE 975
Merck Sharp & Dohme LLC - A Phase 1b2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan T-DXd Monotherapy …
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.